Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Avoid AcelRx Pharmaceuticals Inc (ACRX)?

Is AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They fail miserably sometimes, but historically their consensus stock picks outperformed the market after adjusting for known risk factors.

Is AcelRx Pharmaceuticals the right pick for your portfolio? The stock is not very popular among the funds we track and the number of long hedge fund bets went down by 2 during the third quarter as the stock lost 23% of its value in the same period. However, the level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity, but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Cherokee Inc. (NASDAQ:CHKE), Global Partner Acquisition Corp. (NASDAQ:GPAC), and hhgregg, Inc. (NYSE:HGG) to gather more data points.

Follow Acelrx Pharmaceuticals Inc (NASDAQ:ACRX)
Trade (NASDAQ:ACRX) Now!

In the eyes of most shareholders, hedge funds are assumed to be unimportant, outdated investment vehicles of yesteryear. While there are more than 8000 funds trading today, Our experts choose to focus on the masters of this club, approximately 700 funds. Most estimates calculate that this group of people have their hands on bulk of the smart money’s total capital, and by following their unrivaled picks, Insider Monkey has spotted various investment strategies that have historically outrun the market. Insider Monkey’s small-cap hedge fund strategy surpassed the S&P 500 index by 12 percentage points a year for a decade in their back tests.

With all of this in mind, let’s review the latest action surrounding AcelRx Pharmaceuticals Inc (NASDAQ:ACRX).

How are hedge funds trading AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)?

At the end of the third quarter, a total of 10 of the hedge funds tracked by Insider Monkey held long positions in this stock, a decline of 17% from one quarter earlier. Despite the decline, there still exists a number of investors that own substantial positions in the company.

According to Insider Monkey’s hedge fund database, Perceptive Advisors, managed by Joseph Edelman, holds the most valuable position in AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Perceptive Advisors has a $19.1 million position in the stock, comprising 1.5% of its 13F portfolio. The second most bullish fund is Palo Alto Investors, led by William Leland Edwards, holding a $5.1 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Some other professional money managers with similar optimism include Bihua Chen’s Cormorant Asset Management, D. E. Shaw’s D E Shaw, and Hal Mintz’s Sabby Capital.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.